NASDAQ:XTLB X T L Biopharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding X T L Biopharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.85 -0.01 (-0.54 %) (As of 09/28/2020 12:00 AM ET) Add Compare Share Today's Range$1.78Now: $1.85▼$1.8850-Day Range$1.61MA: $1.85▼$2.2152-Week Range$0.63Now: $1.85▼$2.35Volume1,642 shsAverage Volume15,489 shsMarket Capitalization$9.51 millionP/E RatioN/ADividend YieldN/ABeta0.91 ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for X T L Biopharmaceuticals. Previous Next 2.8 Community Rank Outperform VotesX T L Biopharmaceuticals has received 79 “outperform” votes. (Add your “outperform” vote.)Underperform VotesX T L Biopharmaceuticals has received 61 “underperform” votes. (Add your “underperform” vote.)Community SentimentX T L Biopharmaceuticals has received 56.43% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about X T L Biopharmaceuticals and other stocks. Vote “Outperform” if you believe XTLB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XTLB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldX T L Biopharmaceuticals does not currently pay a dividend.Dividend GrowthX T L Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, X T L Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 8.55% of the stock of X T L Biopharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of X T L Biopharmaceuticals is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X T L Biopharmaceuticals is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX T L Biopharmaceuticals has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.56 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XTLB Previous Symbol CUSIPN/A CIK1023549 Webwww.xtlbio.com Phone972-9955-7080Debt Debt-to-Equity RatioN/A Current Ratio33.03 Quick Ratio28.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.36 per share Price / Book1.36Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-1,350,000.00 Net MarginsN/A Return on Equity-38.54% Return on Assets-37.40%Miscellaneous EmployeesN/A Outstanding Shares5,140,000Market Cap$9.51 million Next Earnings Date11/25/2020 (Estimated) OptionableNot Optionable $1.85 -0.01 (-0.54 %) (As of 09/28/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive XTLB News and Ratings via Email Sign-up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. X T L Biopharmaceuticals (NASDAQ:XTLB) Frequently Asked Questions How has X T L Biopharmaceuticals' stock been impacted by COVID-19? X T L Biopharmaceuticals' stock was trading at $1.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, XTLB stock has increased by 79.6% and is now trading at $1.85. View which stocks have been most impacted by COVID-19. When is X T L Biopharmaceuticals' next earnings date? X T L Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 25th 2020. View our earnings forecast for X T L Biopharmaceuticals. How were X T L Biopharmaceuticals' earnings last quarter? X T L Biopharmaceuticals Ltd (NASDAQ:XTLB) announced its quarterly earnings results on Monday, August, 24th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. View X T L Biopharmaceuticals' earnings history. When did X T L Biopharmaceuticals' stock split? How did X T L Biopharmaceuticals' stock split work? Shares of X T L Biopharmaceuticals reverse split on the morning of Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 9th 2017. An investor that had 100 shares of X T L Biopharmaceuticals stock prior to the reverse split would have 20 shares after the split. Are investors shorting X T L Biopharmaceuticals? X T L Biopharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 5,800 shares, an increase of 65.7% from the August 31st total of 3,500 shares. Based on an average trading volume of 19,100 shares, the short-interest ratio is currently 0.3 days. View X T L Biopharmaceuticals' Short Interest. Who are some of X T L Biopharmaceuticals' key competitors? Some companies that are related to X T L Biopharmaceuticals include PDS Biotechnology (PDSB), Provectus Biopharmaceuticals (PVCT), Aptorum Group (APM), Oncternal Therapeutics (ONCT), Vaccinex (VCNX), Seelos Therapeutics (SEEL), SONNET BioTherapeutics (SONN), Oragenics (OGEN), Acer Therapeutics (ACER), Bellicum Pharmaceuticals (BLCM), Cellectar Biosciences (CLRB), AgeX Therapeutics (AGE), Innovate Biopharmaceuticals (INNT), Dare Bioscience (DARE) and Annovis Bio (ANVS). View all competitors. What other stocks do shareholders of X T L Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other X T L Biopharmaceuticals investors own include Sorrento Therapeutics (SRNE), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Akari Therapeutics (AKTX), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), Gilead Sciences (GILD), Novus Therapeutics (NVUS) and Regulus Therapeutics (RGLS). Who are X T L Biopharmaceuticals' key executives? X T L Biopharmaceuticals' management team includes the following people: Mr. Joshua Levine, Chief Exec. Officer (Age 53)Mr. Itay Weinstein, Chief Financial Officer (Age 48)Mr. Ronen Kantor Adv, Company Sec. What is X T L Biopharmaceuticals' stock symbol? X T L Biopharmaceuticals trades on the NASDAQ under the ticker symbol "XTLB." How do I buy shares of X T L Biopharmaceuticals? Shares of XTLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is X T L Biopharmaceuticals' stock price today? One share of XTLB stock can currently be purchased for approximately $1.85. How big of a company is X T L Biopharmaceuticals? X T L Biopharmaceuticals has a market capitalization of $9.51 million. What is X T L Biopharmaceuticals' official website? The official website for X T L Biopharmaceuticals is www.xtlbio.com. How can I contact X T L Biopharmaceuticals? X T L Biopharmaceuticals' mailing address is 5 BADNER STREET, RAMAT GAN L3, 4365603. The biopharmaceutical company can be reached via phone at 972-9955-7080 or via email at [email protected] This page was last updated on 9/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
